Renhua Guo

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

Medicine, Oncology, Pharmacology +6

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis

Xin Zhou, Wei Wen, Xia Shan et al. · Oncotarget · 2016 · 167 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer

Dandan Yin, Zhijun Liu, Erbao Zhang et al. · Tumor Biology · 2015 · 156 citations

Medicine, Molecular Biology, Oncology +17

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang et al. · Journal of Thoracic Oncology · 2020 · 156 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +12